215 related articles for article (PubMed ID: 25616998)
1. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
Massink MP; Kooi IE; van Mil SE; Jordanova ES; Ameziane N; Dorsman JC; van Beek DM; van der Voorn JP; Sie D; Ylstra B; van Deurzen CH; Martens JW; Smid M; Sieuwerts AM; de Weerd V; Foekens JA; van den Ouweland AM; van Dyk E; Nederlof PM; Waisfisz Q; Meijers-Heijboer H
Mol Oncol; 2015 Apr; 9(4):877-88. PubMed ID: 25616998
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
[TBL] [Abstract][Full Text] [Related]
3. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
4. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
[TBL] [Abstract][Full Text] [Related]
5. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Joosse SA; Brandwijk KI; Mulder L; Wesseling J; Hannemann J; Nederlof PM
Genes Chromosomes Cancer; 2011 Feb; 50(2):71-81. PubMed ID: 21104783
[TBL] [Abstract][Full Text] [Related]
6. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
7. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
8. Subtypes of familial breast tumours revealed by expression and copy number profiling.
Waddell N; Arnold J; Cocciardi S; da Silva L; Marsh A; Riley J; Johnstone CN; Orloff M; Assie G; Eng C; Reid L; Keith P; Yan M; Fox S; Devilee P; Godwin AK; Hogervorst FB; Couch F; ; Grimmond S; Flanagan JM; Khanna K; Simpson PT; Lakhani SR; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Oct; 123(3):661-77. PubMed ID: 19960244
[TBL] [Abstract][Full Text] [Related]
9. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
10. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
12. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
14. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
[TBL] [Abstract][Full Text] [Related]
15. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
16. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
[TBL] [Abstract][Full Text] [Related]
17. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
18.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
19. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Ha KC; Lalonde E; Li L; Cavallone L; Natrajan R; Lambros MB; Mitsopoulos C; Hakas J; Kozarewa I; Fenwick K; Lord CJ; Ashworth A; Vincent-Salomon A; Basik M; Reis-Filho JS; Majewski J; Foulkes WD
BMC Med Genomics; 2011 Oct; 4():75. PubMed ID: 22032724
[TBL] [Abstract][Full Text] [Related]
20. [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
Vincent-Salomon A; Macgrogan G; Charaffe-Jauffret E; Jacquemier J; Arnould L
Bull Cancer; 2010 Mar; 97(3):357-63. PubMed ID: 20197250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
